预约演示

Lindsay Rosenwald’s Fortress Bio ‘Uniquely’ Positioned to Capitalize on Current Long Biotech Winter

2022-10-31

基因疗法合作抗体免疫疗法优先审批

None

Dr. Lindsay Rosenwald has created and sold numerous companies during his decades-long biopharma career. He came out of retirement in 2013 to create Fortress Biotech ($FBIO) because he saw an opportunity to fill a gap in drug development while also driving investor returns.

“By our count, roughly over $350 billion is invested globally each year in biopharma R&D, and that’s still not nearly enough,” said Rosenwald. “TherFortress Biotechuality drug candidates than there are people and capital to develop them, and that gap has grown significantly over the past couple of years.”

As the SPDR S&P Biotech ETF ($XBI) has dropped roughly 50-70% during the past 20 months, dozens of companies have announced plans to shelve development programs to conserve cash rather than attempt to raise funds at depressed valuations. There has also been a trickle-down effect. According to Crunchbase, venture biotech funding is down more than 38% in 2022 compared with 2021.

Fortress Bio’s unique business model

Fortress Biosn’t create new molecules. It leverages a large internal and external business development team to find, evaluate and primarily aims to acquire assets that have been significantly de-risked with strong clinical data and then builds companies to advance those programs (it currently has 11 partner companies). Ultimately, Fortress looks to generate shareholder returns through three channels: asset monetizations, growth in equity holdings in its partner companies and dividend and royalty revenue paid by its partner companies in return for the significant business development activities, as well as operational and strategic support, that Fortress provides. Most partner companies pay Fortress an annual equity dividend worth 2.5% of the partner’s market cap and a royalty of 4.5% on net sales.

Currently, Fortress has nine marketed products and 20 clinical development programs across its partner companies in therapeutic areas ranging from oncology ($CKPT), rare diseases ($ATXI) and cell/gene therapy ($MBIO) to commercial dermatology. Partner company Journey Medical Corporation ($DERM) achieved record dermatology revenues of $63.1M in 2021.

“Our model is designed to try to decrease risk and expense while at the same time creating a regular flow of value-creating events for our shareholders,” said Rosenwald. “We’ve always been incredibly selective with our acquisitions, and now the bar is higher bJourney Medical Corporationtunities available.”

The model in action

In January 2017, Fortress created Caelum Biosciences after it in-licensed CAEL-101, a monoclonal antibody (mAb) that was being evaluated as a potential treatment for the treatment of a rare systemic disorder called amyloid light chain amyloidosis in a Phase 1a/1b study, from a leading university.

After announcing positive Phase 1aCaelum Biosciencesess entered into a colCAEL-101on with Alexion Pharmaceuticals to develop CAEL-101 in January 2019. Alexion acquired a minority equity intesystemic disorderd an excamyloid light chain amyloidosismaining Caelum equity based on Phase 2 data for a pre-negotiated amount. Over the next two and a half years, Alexion funded CAEL-101 development to the tune of $140M.

In October 2021, AstraZeneca (which acquired Alexion in June 2021) exercised its option toAlexion Pharmaceuticals of Caelum BCAEL-101es, triggering an Alexion $150M payment to all other Caelum shareCaelums, approximately $64M of which went Fortress. CaelCaelumreholders are still eligible to receive additional payments totaling up to $350M, including up AlexionM to ForCAEL-101ayable upon the achievement of regulatory and commercial milestones. CAEL-101 is currently enrolling across two global Phase 3 studies that could support approvals.

“CAEL-101 epitomiAstraZenecaque model,” says Alexionld. “Our business development team was able to identify a valuablCaelum Bioscienceslent early human efficacy data that had not yet beeCaelumished or presented to the public. The Caelum team efficienCaelumved CAEL-101 through Phase 2, and then we were able to negotiate an excellent deal for Fortress and Caelum shareholders with significant upfront payments and the potential for hundreds of milCAEL-101re.”

LCAEL-101, Fortress partner company Cyprium Therapeutics announced execution of an asset purchase agreement with a commercial-stage rare disease company, Sentynl Therapeutics, for CUTX-101 for the treatment of Menkes disease, whicCaeluments infants from properCAEL-101bing copper and could lead to death in early childhood.Caelum

Cyprium is eligible to receive up toCyprium Therapeuticselopment and regulatory cash milestones through NDA approval from Sentynl, as well as potential saSentynl TherapeuticsoyaltiCUTX-101ium will retain 100% oMenkes diseaseany FDA priority review voucher that may be issued at NDA approval for CUTX-101. Recently, these vouchers have sold for $100-110M each.

Cypriumg milestonesSentynl Cyprium FDA CUTX-101

Fortress has more potential value inflection points than many similar sized companies. Among the upcoming events in which investors are focused on include:

Urica Therapeutics is expected to report Phase 1 data for dotinurad early next year. Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor for gout and possibly other hyperuricemic indications including chronic kidney disease and heart failure. Dotinurad can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabsorption in the kidneys. Dotinurad was approved and launched in Japan in 2020 as an oral therapy for gout and hyperuricemia. Fortress believes dotinurad may have blockbuster potential in its licensed markets, including the U.S. and E.U.

Urica Therapeuticsutics ($CKPT) is expected to file a Bioldotinuradense Application (Dotinuradthe company’s anti-PD-L1 antibody candidate, cosibelimab, in patients gout metastatic or locally advanced cutaneous squamous cell chronic kidney disease has heart failure tDotinuradst-in-class drug that could disrupt the ~$25B+ checkpoint imURAT1herapy market and capture meaningful market Dotinurada lower-priced alternative to currently available anti-PD-(L)1s, sugouts Keyhyperuricemia and Libtayo.dotinurad

Checkpoint Therapeuticsg and finding assets where others are not,” added Rosenwald. “I’ve never been more exanti-PD-L1 antibody opportuniticosibelimabI am confident thatmetastatic or locally advanced cutaneous squamous cell carcinomaenCosibelimabingful treatments for patients while rewarding our investors and shareholders.”Keytruda Opdivo Libtayo